GSA Capital Partners LLP Acquires 26,617 Shares of Moderna, Inc. $MRNA

GSA Capital Partners LLP raised its holdings in shares of Moderna, Inc. (NASDAQ:MRNA) by 216.3% during the third quarter, HoldingsChannel reports. The firm owned 38,922 shares of the company’s stock after purchasing an additional 26,617 shares during the period. GSA Capital Partners LLP’s holdings in Moderna were worth $1,005,000 as of its most recent SEC filing.

Several other large investors have also modified their holdings of the business. Parkside Financial Bank & Trust lifted its holdings in Moderna by 19.0% during the second quarter. Parkside Financial Bank & Trust now owns 2,347 shares of the company’s stock worth $65,000 after buying an additional 375 shares during the period. Amalgamated Bank increased its holdings in shares of Moderna by 0.6% in the 2nd quarter. Amalgamated Bank now owns 65,458 shares of the company’s stock valued at $1,806,000 after acquiring an additional 408 shares during the period. Rothschild Investment LLC raised its position in shares of Moderna by 94.1% in the 2nd quarter. Rothschild Investment LLC now owns 920 shares of the company’s stock worth $25,000 after acquiring an additional 446 shares in the last quarter. 180 Wealth Advisors LLC lifted its stake in shares of Moderna by 2.8% during the 2nd quarter. 180 Wealth Advisors LLC now owns 23,928 shares of the company’s stock worth $660,000 after purchasing an additional 642 shares during the last quarter. Finally, State of Michigan Retirement System lifted its stake in shares of Moderna by 0.8% during the 2nd quarter. State of Michigan Retirement System now owns 92,541 shares of the company’s stock worth $2,553,000 after purchasing an additional 700 shares during the last quarter. Institutional investors own 75.33% of the company’s stock.

Insider Buying and Selling

In other Moderna news, Director Noubar Afeyan sold 23,853 shares of the company’s stock in a transaction on Thursday, December 11th. The stock was sold at an average price of $29.48, for a total value of $703,186.44. Following the completion of the sale, the director directly owned 3,924 shares in the company, valued at $115,679.52. This represents a 85.87% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 10.90% of the company’s stock.

Key Moderna News

Here are the key news stories impacting Moderna this week:

• Positive Sentiment: FDA reverses course and will review Moderna’s mRNA flu vaccine (mRNA‑1010), with an Aug. 5, 2026 target date — this restores a clear pathway to potentially have a product available for the 2026‑27 season and is the main driver of today’s share strength. FDA agrees to review Moderna’s mRNA flu vaccine application in a reversal (CNBC)
• Positive Sentiment: Brokerage/analyst commentary is supportive — at least one note (Goldman Sachs referenced) expects upside for MRNA, which can amplify buying after the FDA news. Moderna (NASDAQ:MRNA) Stock Price Expected to Rise, The Goldman Sachs Group Analyst Says
• Neutral Sentiment: Moderna scheduled investor presentations at TD Cowen and Barclays in early March — provides management a forum to discuss regulatory progress, commercialization plans and financial outlook, but is informational rather than catalytic. Moderna to Present at Upcoming Conferences in March 2026
• Negative Sentiment: BioNTech filed a patent‑infringement suit against Moderna in Delaware, alleging Moderna’s COVID‑19 shot mNexspike infringes patents tied to BioNTech/Pfizer’s Comirnaty — this introduces potential damages, injunction risk and longer‑term legal overhang. BioNTech sues Moderna for patent infringement over COVID-19 shots (Reuters)
• Negative Sentiment: A court recently rejected two of Moderna’s defenses in a separate patent dispute with Arbutus, signaling increased legal exposure on mRNA‑related IP that could lead to further rulings or settlements. Court Rejects Two Moderna Defenses in mRNA Vaccine Patent Row With Arbutus

Analyst Ratings Changes

Several equities analysts have issued reports on MRNA shares. Jefferies Financial Group reiterated a “hold” rating on shares of Moderna in a research note on Monday, January 5th. JPMorgan Chase & Co. cut their price objective on shares of Moderna from $26.00 to $25.00 and set an “underweight” rating on the stock in a research report on Thursday, October 23rd. Morgan Stanley set a $30.00 price objective on shares of Moderna in a research note on Monday. BMO Capital Markets upgraded shares of Moderna from a “market perform” rating to a “buy” rating in a research note on Monday, January 12th. Finally, Wolfe Research reaffirmed an “underperform” rating and issued a $17.00 price target on shares of Moderna in a report on Thursday, November 20th. Two research analysts have rated the stock with a Buy rating, thirteen have issued a Hold rating and five have assigned a Sell rating to the company. Based on data from MarketBeat.com, Moderna has an average rating of “Reduce” and a consensus price target of $31.47.

Moderna Stock Up 6.7%

MRNA opened at $49.70 on Friday. The company has a quick ratio of 3.22, a current ratio of 3.29 and a debt-to-equity ratio of 0.07. The company has a 50-day moving average price of $38.61 and a 200 day moving average price of $30.29. The company has a market cap of $19.42 billion, a PE ratio of -6.84 and a beta of 1.32. Moderna, Inc. has a twelve month low of $22.28 and a twelve month high of $55.20.

Moderna (NASDAQ:MRNA) last announced its earnings results on Friday, February 13th. The company reported ($2.11) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.79) by $0.68. The company had revenue of $678.00 million for the quarter, compared to analysts’ expectations of $611.14 million. Moderna had a negative net margin of 145.16% and a negative return on equity of 30.15%. The firm’s quarterly revenue was down 33.2% on a year-over-year basis. During the same quarter in the previous year, the company posted ($2.91) EPS. Sell-side analysts expect that Moderna, Inc. will post -9.61 earnings per share for the current fiscal year.

Moderna Profile

Moderna, Inc is a biotechnology company headquartered in Cambridge, Massachusetts, specializing in messenger RNA (mRNA) therapeutics and vaccines. The company’s platform leverages synthetic mRNA to instruct cells to produce proteins that can prevent or treat diseases. Since its founding in 2010, Moderna has advanced from early-stage research into a broad pipeline of vaccine and therapeutic candidates designed to address infectious diseases, rare genetic disorders and chronic illnesses.

Moderna’s flagship product is its mRNA-based COVID-19 vaccine, which was the first of its kind to receive emergency use authorization and later full approval in multiple jurisdictions.